Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Resources Pharmaceutical GroupSTU:640 -1.92%60 ROC (Joel Greenblatt) % is 11.83% as of Dec. 2025, which is 62% below its 10-year median of 30.73. GuruFocus rates STU:640 with a GF Score™ of 60/100 and a GF Value™ of €0.64 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 982 Drug Manufacturers companies, China Resources Pharmaceutical Group ranks better than 54.18% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. China Resources Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.83%.
The historical rank and industry rank for China Resources Pharmaceutical Group's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:640'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.62 Med: 30.73 Max: 40.32
Current: 13.62
During the past 13 years, China Resources Pharmaceutical Group's highest ROC (Joel Greenblatt) % was 40.32%. The lowest was 13.62%. And the median was 30.73%.
STU:640's ROC (Joel Greenblatt) % is ranked better than 54.18% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.495
vs STU:640: 13.62
China Resources Pharmaceutical Group (STU:640) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group ROC (Joel Greenblatt) % Chart
STU:640 vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's ROC (Joel Greenblatt) % falls into.
China Resources Pharmaceutical Group ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 11.83% mean?
China Resources Pharmaceutical Group (STU:640) has a ROC (Joel Greenblatt) % of 11.83% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on China Resources Pharmaceutical Group and its competitors. This is 62% below median its historical median of 30.73. Over the past decade, China Resources Pharmaceutical Group's ROC (Joel Greenblatt) % has ranged from 13.62 to 40.32. According to the industry distribution chart, China Resources Pharmaceutical Group ranks #450 out of 982 companies in the Drug Manufacturers industry, placing it in the top 45.8%.
Is China Resources Pharmaceutical Group's ROC (Joel Greenblatt) % too high?
China Resources Pharmaceutical Group's current ROC (Joel Greenblatt) % of 11.83% is 62% below median its 10-year median of 30.73. Over the past 10 years, this metric has ranged from a low of 13.62 to a high of 40.32. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.50. China Resources Pharmaceutical Group's value of 11.83% is 2.9% above this industry median. Based on the distribution chart, China Resources Pharmaceutical Group ranks #450 out of 982 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Pharmaceutical Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Pharmaceutical Group ranks #450 out of 982 companies for ROC (Joel Greenblatt) %. This puts China Resources Pharmaceutical Group in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.50. China Resources Pharmaceutical Group's value of 11.83% is 2.9% above this benchmark. Historically, China Resources Pharmaceutical Group's own ROC (Joel Greenblatt) % has ranged from 13.62 to 40.32 over the past decade. While the company's 10-year median is 30.73 vs. the industry median of 11.50, China Resources Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.50, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Pharmaceutical Group's current ROC (Joel Greenblatt) % of 11.83% is 2.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on China Resources Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current ROC (Joel Greenblatt) % is 11.83%, which is 62% below median its own 10-year median of 30.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.64, compared to a current price of €0.51 — trading 20.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 11.83%, which is 62% below median its 10-year median of 30.73 and 2.9% above the Drug Manufacturers industry median of 11.50. China Resources Pharmaceutical Group's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current ROC (Joel Greenblatt) % is 11.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.51 is trading 20.3% below its estimated GF Value™ of €0.64.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
ROC (Joel Greenblatt) %: 11.83% (62% below median its 10-year median of 30.73)
GF Value™: €0.64 vs. price of €0.51 (20.3% below fair value)
Industry Position: 2.9% above the Drug Manufacturers median (#450 of 982)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
60GF Score
Get the complete analysis for STU:640
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
